Streetbeat News

NBTX

Nanobiotix S.A.

https://www.nanobiotix.com

Industry

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Open

3.49

Mkt cap

164M

Volume

17K

High

3.49

P/E Ratio

-4.53

52-wk high

8.96

Low

3.32

Div yield

N/A

52-wk low

2.76

Nanobiotix reported cash and cash equivalents of €58.9 million as of March 31, 2024, which is expected to fund operations into Q3 2025, including a $20 million milestone received.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 6:24 am

Nanobiotix has updated its corporate strategy to focus on long-term growth through its global NBTXR3 collaboration. Key updates include the transfer of sponsorship for a Phase 3 trial in head and neck cancer, regulatory pathway optimizations, and a new Phase 2 study in lung cancer approved by the US FDA.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:20 pm

NANOBIOTIX announced that the FDA has issued a 'Study May Proceed' letter for a randomized Phase 2 study evaluating NBTXR3 in Stage Three Lung Cancer. This marks a significant step forward in the development of NBTXR3, potentially impacting its future market position and investor sentiment towards NANOBIOTIX.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:27 pm

Nanobiotix (NASDAQ:NBTX) reported FY 2023 GAAP EPS of $(1.17), surpassing the $(1.66) estimate, and sales of $39.323M, exceeding the $13.680M estimate. This represents a significant improvement over the previous year, with a 32.37% decrease in losses per share and a 681.30% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 9:42 pm

CarMax, Inc. reported lower-than-expected Q4 earnings, leading to a 9.1% drop in pre-market trading. Other stocks like The Lovesac Company, Nyxoah S.A., AVITA Medical, Inc., DigiAsia Corp., Nanobiotix S.A., Grifols, S.A., Fastenal Company, and Mercury General Corporation also saw declines in pre-market trading due to various reasons including disappointing earnings, downgrades, and upcoming earnings expectations.